Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Secondary Spinal Cord Injury llI: Pathophysiology01:25

Secondary Spinal Cord Injury llI: Pathophysiology

Early Ischemia and Ionic ImbalanceWithin minutes of spinal cord injury, a secondary cascade begins, progressing over hours to weeks. Vascular damage reduces blood flow, causing ischemia and mitochondrial dysfunction. ATP depletion leads to ion pump failure, membrane depolarization, sodium influx, potassium efflux, and water accumulation, resulting in cellular swelling. Increased intracellular calcium further disrupts mitochondria and accelerates cellular injury.Excitotoxicity and Neuronal...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Degenerative Disc Disease ll: Pathophysiology01:23

Degenerative Disc Disease ll: Pathophysiology

The symptoms of degenerative disc disease arise from a combination of mechanical compression, vascular compromise, and biochemical inflammation, which together disrupt nerve function and produce pain.Mechanical CompressionDisc degeneration reduces height and elasticity, predisposing to herniation of the nucleus pulposus, a major cause of radicular pain. Herniations may be protrusion (bulging with intact annulus), extrusion (nucleus extends beyond disc but remains connected), or sequestration...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Spinal Cord Injury ll: Pathophysiology01:14

Spinal Cord Injury ll: Pathophysiology

Spinal cord injury progresses through two interconnected phases: primary injury and secondary injury.Primary InjuryPrimary injury happens at the moment of trauma and involves immediate mechanical damage to the spinal cord.Compression happens when broken vertebrae, herniated discs, or accumulating blood (such as a hematoma) press directly against the spinal cord, distorting its normal shape and function. In cases of contusion, the cord is bruised by a blunt force (like penetrating injuries or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of pediatric SARS-CoV-2 healthcare-associated infection outbreaks in Germany, 2020-2023: a retrospective observational study.

European journal of pediatrics·2025
Same author

Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines.

Multiple sclerosis and related disorders·2024
Same author

Comparing infusion-related reactions of the first full dose (600 mg) biosimilar ocrelizumab administration with the standard divided protocol in multiple sclerosis patients: a randomized controlled trial study.

Acta neurologica Belgica·2023
Same author

Epidemiology of healthcare-associated SARS-CoV-2 outbreaks in Germany between March 2020 and May 2022.

The Journal of hospital infection·2023
Same author

Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.

Journal of neurology·2023
Same author

Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis.

AJNR. American journal of neuroradiology·2023

Related Experiment Video

Updated: Jun 17, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Black holes in multiple sclerosis: definition, evolution, and clinical correlations.

M A Sahraian1, E-W Radue, S Haller

  • 1Sina MS Research Center, Sina Hospital, Tehran University of Medical Sciences, Iran. msahrai@sina.tums.ac.ir <msahrai@sina.tums.ac.ir>

Acta Neurologica Scandinavica
|December 17, 2009
PubMed
Summary

Magnetic resonance imaging (MRI) black holes may indicate axonal loss in multiple sclerosis (MS). Further research is needed to correlate black holes with clinical outcomes and therapeutic effects in MS patients.

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Related Experiment Videos

Last Updated: Jun 17, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

Area of Science:

  • Neuroimaging
  • Neurology
  • Radiology

Background:

  • Magnetic resonance imaging (MRI) is crucial for multiple sclerosis (MS) diagnosis and monitoring.
  • T2-hyperintense lesions lack specificity for disease activity due to varied contributors.
  • Neurodegeneration is increasingly recognized in MS pathophysiology.

Purpose of the Study:

  • To explore the utility of T1-hypointense lesions (black holes) as markers of axonal loss in MS.
  • To investigate the correlation between persistent black holes and clinical outcomes.
  • To assess the impact of therapy on longitudinal changes in black hole volume.

Main Methods:

  • Utilizing advanced MRI techniques like magnetization transfer imaging and magnetic resonance spectroscopy.
  • Analyzing the formation and evolution of chronic T1-hypointense lesions.
  • Correlating imaging findings with clinical data and therapeutic interventions.

Main Results:

  • T1-hypointense lesions (black holes) are proposed markers of axonal loss and neuronal destruction in MS.
  • Current correlation between persistent black holes and clinical outcomes remains uncertain.
  • Limited data exists on therapy's effect on T1-hypointense lesion volume over time.

Conclusions:

  • Measuring black holes in MS clinical studies may enhance understanding of disease pathophysiology.
  • Black hole assessment could offer an additional method for evaluating therapeutic efficacy in MS.
  • Further research is warranted to validate black holes as reliable biomarkers for MS progression and treatment response.